Celera diagnostic

Businesses • BACK • Businesses at GE • Additive (link is external) • Aerospace (link is external) • Capital (link is external) • Digital (link is external) • Power • (link is external) • (link is external) • (link is external) • (link is external) • (link is external) • Renewable Energy • (link is external) • (link is external) • (link is external) • (link is external) • (link is external) • (link is external) • Research (link is external) • Licensing • Email • Globe • • Email • Globe • Search • NISKAYUNA, N.Y., ROCKVILLE, Md. & ALAMEDA, Calif.--(BUSINESS WIRE)--July 12, 2004-- Initial Project to Focus on Novel Markers and Imaging Agents for Cancer General Electric Company (NYSE:GE), through GE Global Research, along with Celera Genomics Group (NYSE:CRA), an Applera Corporation business, and Celera Diagnostics, a joint venture between Celera Genomics and the Applied Biosystems Group (NYSE:ABI) of Applera, today announced a joint research collaboration intended to accelerate the discovery and development of new products for personalized, or targeted, medicine. The parties will seek to understand and differentiate disease at the molecular level, which is expected to lead to new diagnostics and treatments that are tailored for a specific disease and/or patient population. The first project outlined in the research collaboration is intended to support GE's development of novel imaging agents for cancer that selectively target cell surface proteins that Celera Genomics has iden...

Celera genomics is a subsidiary of Quest diagnostics, which works in the field of genetic engineering related to technologies. It is a business unit of Applera, a company found in 2008 that acquired by Quest diagnostics in the year 2011. Celera Genomics is a biotechnology company that specialized in genomics. Celera is a company that is a part of the larger organization Quest Diagnostics. This company primarily focuses on biotechnology and therapeutic research. Quest Diagnostics has a lot of labs that offer diagnostic services for a wide amount of diseases. This company was found in 1998 by an American geneticist named Craig Venter. It began as a company whose sole focus was on the human genome project. Eventually, Celera also went on to sequence the genome of the fruit fly in 2000. A genome of an organism refers to a collection of all the genetic material that is present in the chromosomes of an organism. This means that a genome has the DNA sequence or a blueprint of the entire body. Getting a sequence of the entire genome is extremely useful because a person can use this information to analyze certain genes in the body. The process of extracting the entire genome of any organism is extremely tough, which is why no one had ever sequenced the entire genome before this. The human genome consists of approximately 3 million base pairs that are arranged into 23 pairs of chromosomes in the body. All of these sequences are made up of only 4 nitrogen bases as adenine, thymine, g...

Celera Genomics, a Rockville, Md.-based biotechnology company, couldn’t have cracked the human genome without information technology. It’s a point Kathy Ordoñez——president of Celera Genomics, which develops drugs to treat psoriasis, cancer and asthma, and its sister company, Celera Diagnostics, which creates genetic testing tools—knows all too well. Celera needs its systems to crunch algorithms and sort through millions of genetic possibilities to find relationships between genes—for, say, taste and smell—and a condition like heart disease. Ordoñez left pharmaceutical giant Hoffmann-LaRoche in 2000 to become president of Celera Diagnostics, based in Alameda, Calif. In 2002, she took the reins of Celera Genomics from founder J. Craig Venter, who pushed Celera to use technology to decipher the human genome. Ordoñez’s mandate: commercialize the company’s findings. Celera Genomics and Diagnostics reported a collective operating loss of $140 million on revenue of $66 million for the year ended June 30. Baseline business editor Larry Dignan recently sat down with Ordoñez to discuss how Celera uses technology to explore the human condition. How important are information systems to commercializing Celera’s discoveries? The work we do both at Celera Genomics and at Celera Diagnostics is very technical. In both groups, we have very large-scale ongoing discovery programs. At Celera Genomics in Rockville, we have been studying cell-surface antigens [substances that spur the body to cr...

Americas+1 212 318 2000 EMEA+44 20 7330 7500 Asia Pacific+65 6212 1000 • Company • • • • • • • • • Communications • • Follow • • • • • • Products • • • • • Industry Products • • • • • Media • • • • • • • • • • Media Services • • • Company • • • • • • • • • Communications • • Follow • • • • • • Products • • • • • Industry Products • • • • • • Media • • Technology • • • • Businessweek • • • • Media Services • • • Bloomberg Bloomberg Wall Street Week Bloomberg Wall Street Week, hosted by David Westin, is a reinvention of the iconic Wall Street Week, which aired on PBS for over 30 years and was hosted by late financial journalist Louis Rukeyser. The one-hour program features market and geopolitical discussions with a rotating panel of influential voices including thought leaders, CEOs, policy makers and economists. Bloomberg Originals Africa+ Africa is quickly becoming one of the business world's most supercharged areas, with a burgeoning startup scene, expansive infrastructure projects, and capital pouring in from across the world. In this series, Quicktake Originals takes an in-depth look at the domestic and international projects that are shaping modern Africa, and their implications for the global economy. Also streaming on your TV:

Novanta is a trusted technology partner to original equipment manufacturers in the medical and advanced industrial technology markets. The Company provides innovative and enabling solutions with photonics, vision, and precision motion technologies. Novanta's common shares are quoted on NASDAQ under the ticker symbol "NOVT.